Rigetti Computing reported its second-quarter results this week, and on paper they read as a paradox. Revenue rose 183% from a year earlier to about $5.1 million, roughly matching estimates, yet the company posted a GAAP net loss of $52.6 million, and the stock slipped after the report as investors fixed on the widening losses, the heavy spending, and the acknowledgment that commercial quantum advantage remains years away. Judged as a business, this looks dreadful: a company losing on the order of ten dollars for every dollar of revenue it books.
But judging Rigetti as a business is a category error, and it is the mistake that causes most of the confusion around quantum-computing stocks. Rigetti is not really a business yet. It is a long-dated option on a technological breakthrough that may or may not arrive, and once you look at it that way, nearly everything about how it trades, including this quarter's odd reaction, snaps into focus.
The financials measure the wrong thing
Start with why the income statement is so misleading here. A $5.1 million revenue line and a $52.6 million loss describe a catastrophic business, but Rigetti is not attempting to be a profitable business right now. It is spending heavily, and the research and development behind those losses is the spending, to try to win a race toward commercially useful quantum computing. Seen that way, the losses are not evidence of failure. They are the price of staying in the game long enough to have a chance at the prize.
And the revenue, real growth notwithstanding, is nearly beside the point. Five million dollars a quarter is a rounding error measured against either outcome that actually matters: the prize, a share of a potentially vast market if fault-tolerant quantum computing becomes real, or the risk, a value near zero if the technology never becomes commercially useful or a competitor gets there first. The quarterly financials tell you very little about which of those outcomes is more likely, and it is that question, not the P&L, that determines what the company is worth.
A stock like this is a call option, not a company
The more useful frame is to treat Rigetti as a long-dated call option on a technological outcome, because an option's value is set by four things, and each maps cleanly onto a quantum stock. The first is the size of the payoff, which here is enormous, since commercially useful quantum computing could open a huge market. That is precisely why the stock can carry a large valuation on tiny revenue: you are paying for the tail, not the trailing sales.
The second is the probability of reaching the payoff, which is low and genuinely unknowable. It is an open question whether fault-tolerant quantum computing will arrive at all on any relevant timeline, and a further open question whether Rigetti's superconducting, chiplet-based approach will win against IBM, Google, and trapped-ion rivals like IonQ. The third is time to expiry, which for a cash-burning company is the runway: Rigetti's roughly $569 million cash cushion is the option's time value, the measure of how long it can keep playing, while its operating loss of around $28 million a quarter is the clock ticking down toward the point where it would need to raise more money or stop. The fourth is volatility, which is extreme, the stock is down about 24% for the year yet rose 43% in a single quarter, and that violence is simply what an option on a binary, distant, uncertain outcome looks like as the market's estimate of the odds lurches on every piece of news. The losses are the premium; the cash is the time on the clock; the wild swings are the option repricing itself.
Why "met estimates but fell" makes sense
This frame also dissolves the paradox of a stock falling on a quarter that met expectations. If you think of Rigetti as a business, meeting estimates should be neutral to good. If you think of it as an option, the quarterly numbers barely move its value at all, because they are noise relative to the payoff, probability, and timing that actually price the option. So with the headline figures roughly as expected, the market's attention drifted to the variables that do matter, and found them unimproved. The burn continued, eroding the time value. And management reiterated that commercial advantage is still years away, meaning neither the probability nor the timing had gotten better.
Meeting a rounding-error revenue estimate does not move an option. Being reminded that the breakthrough is distant and uncertain does. The stock fell not because the business had a bad quarter but because the market re-weighted the option's real drivers and concluded that, if anything, a little more cash had been spent while the prize sat exactly as far off as before.
The insider-selling data point
The option frame also sharpens a fact that deserves sober attention. In the prior quarter, Rigetti insiders sold roughly $17.5 million in stock, and the chief technology officer alone sold about $12.7 million, cutting his personal stake by more than 60%. The people with the best possible information about the probability that this breakthrough actually lands, the company's technical leadership, converted a large portion of their own options into cash.
This proves nothing by itself, and it is important to say so plainly. Insiders sell for many innocent reasons, diversification, taxes, the ordinary need to fund a life, a single quarter's selling is not a verdict, and heavy insider selling is common across hyped stocks of every kind. But when the entire value of an enterprise rests on an uncertain future event, and the individuals best positioned to judge the odds of that event are cashing out substantially into a hype-driven rally, it is at minimum a data point worth weighing honestly rather than waving away. It is a small, candid signal of how the best-informed participants are pricing their own options, and it happens to point the cautious way.
The government stake, a mixed signal
One more recent development cuts in two directions. In May, Rigetti signed a letter of intent with the Commerce Department for up to $100 million in CHIPS Act funding over three years, which lengthens the runway, more time value, and lends a measure of validation that nudges the perceived probability upward, both good for the option's survival. Yet the arrangement contemplates the government taking an equity stake in the company, part of a broader recent pattern of federal equity positions in strategically important technology firms, and that dilutes existing shareholders while underscoring that Rigetti cannot fund this race on its own. The funding is a genuine positive for how long the option can stay alive, paired with a reminder of the company's dependence on outside capital to keep it there. That is a fact about the structure of the bet, offered here without any judgment on the wisdom of the underlying industrial policy.
What the frame does and doesn't tell you
The value of the option lens is that it cuts both ways, which is exactly why thoughtful people land on opposite sides of a stock like this. The bullish case is entirely rational: a small position in a long-dated option on a potentially transformative technology can make sense, because the payoff if quantum computing arrives and Rigetti is among the winners is enormous, and the most you can lose is what you put in. The bearish case is equally rational: the great majority of such options expire worthless, the probability here is low and unknowable, the timeline is long, the cash is burning, the competitors are formidable, and the insiders are selling. Both views can be correct at once, because they are simply different wagers on the same option.
The genuine error, and it is one the euphoric buyer and the scornful skeptic are equally prone to, is analyzing Rigetti as a business at all, reaching for revenue growth or profitability or an earnings multiple as though those settle anything. They do not, because there is not yet a business underneath them worth valuing that way. There is an option, and options are priced on payoff, probability, time, and volatility, not on a single quarter's income statement.
So the question worth asking about these results is not whether Rigetti had a good quarter, which is nearly irrelevant, but whether the option grew more or less valuable, which turns on whether the breakthrough moved closer or became likelier, not on whether $5.1 million cleared a $5.09 million estimate. By that scorecard, the quarter changed little. There was real technical progress, but the payoff remained distant, the probability remained unknowable, the cash kept burning, and the insiders kept selling. The stock fell because the market was briefly reminded of what it is actually holding: an option whose expiry is far away and whose exercise is deeply uncertain. Whether that option is worth its current price is a real and contested judgment, and reasonable investors will answer it differently. But it is a judgment that should be made about an option, sized small and held with clear eyes about the odds, and not about a company having a good or a bad year.
Primary sources
- Barron's for the framing of Rigetti's earnings and stock.
- Investing.com's Q2 2026 earnings-call coverage for revenue of approximately $5.1 million versus $1.8 million a year earlier, the after-hours decline, the observation that investors focused on widening losses and the fact that commercial quantum advantage remains years away, the note that the stock appears overvalued relative to fair value and trades with high volatility, and the Cepheus-1-108Q system specifications and Rigetti's position among the few companies with gate-based systems above 100 qubits.
- StockTitan and GlobeNewswire for the $52.6 million GAAP net loss, six-month revenue of $9.5 million, the HPE and Pittsburgh Supercomputing Center collaboration, the Commerce Department letter of intent for up to $100 million with a contemplated government equity stake, and CEO Subodh Kulkarni's remarks.
- Blockonomi and TipRanks for the consensus estimates, the roughly 24% year-to-date decline, the approximately $17.5 million in insider stock sales, including the CTO's roughly $12.7 million sale reducing his stake by 60.5%, and analyst price targets.
- Yahoo Finance and Zacks for the comparison among Rigetti, D-Wave, and IonQ and the second-quarter surges, with Rigetti up 43% and D-Wave up 75%.
- 24/7 Wall St. for the roughly $569 million cash cushion, the characterization of quantum stocks as speculative, pre-profit bets outside core-portfolio territory, and prior-quarter context.
- The Yahoo Finance earnings-call transcript for the 183% year-over-year revenue growth, gross margin of 43% versus 31%, and operating loss of $28.1 million.
- Seeking Alpha for the post-report share dip.